Impact of Native Chicory Inulin on Change and Persistence of Gut Microbiota
NCT ID: NCT06528041
Last Updated: 2025-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
52 participants
INTERVENTIONAL
2024-08-01
2026-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To what extent do differences exist in rate of change over time between individuals in gut microbiota response (Bifidobacterium growth) to native chicory inulin supplementation.
* To what extent do differences exist between individuals in persistence of the gut microbiota upon stopping supplementation.
The effects of native chicory inulin on gut microbiota response will be compared to a maltodextrin placebo to sure changes in gut microbiota result directly from chicory inulin supplementation.
Participants will firstly complete a one-week run-in phase to establish baseline data and will then be allocated to either native chicory inulin or maltodextrin supplementation for 6 weeks. Inulin will be delivered at 12 g/day split into 2 x 6g portions. Maltodextrin will be calorie matched at 6 g/day split into 2 x 3g portions. This will then be followed by a 6 week post-supplementation phase. Fecal and blood samples will be collected regularly throughout all phases for analysis of gut microbiota and compounds of interest. Participants will also record any changes in gastrointestinal sensation, bowel habits and mood in a diary. Changes in appetite sensation will also measured.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gastrointestinal Toleration of Inulin Products
NCT00958529
Chicory Fiber Effect on Satiety and GI Tolerance
NCT04067362
Influence of Food Matrix on Prebiotic Efficacy in Inulin Type Fructans
NCT05581615
Impact of Dietary Fibre Consumption on Digestive Comfort
NCT05830032
Dietary Fibers Effect on the Gut Microbiota Composition
NCT04114513
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pure Inulin
12 g/day prebiotic supplement
Inulin
12 g/day prebiotic supplement taken daily split into 2 dosages of 6 g dissolved in water
Placebo
6 g/day maltodextrin
Maltodextrin
6 g/day maltodextrin taken daily split into 2 dosages of 3 g dissolved in water
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inulin
12 g/day prebiotic supplement taken daily split into 2 dosages of 6 g dissolved in water
Maltodextrin
6 g/day maltodextrin taken daily split into 2 dosages of 3 g dissolved in water
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI \>18.5 - \< 30 kg/m2
* Regular bowel movements (\> 4 days per week)
Exclusion Criteria
* Self-reported food allergies and sensitivities including gluten, dairy, nuts, soya and lactose etc.
* Self-reported antibiotic treatment in the past 6 months.
* Self-reported history of gastrointestinal disease and/or heart disease, cardiovascular, liver, and respiratory disorders, cancer and/or clinically relevant (pre) diabetes.
* Self-reported to having undergone major surgery of the gastrointestinal tract, with the exception of cholecystectomy and appendectomy.
* Self-reported smoking and/or self-reported drug or alcohol abuse.
* Self-reported history of psychiatric and/or mood disorders including eating disorders.
* Self-reported to be following a restrictive diet (i.e. ketogenic, intermittent fasting).
* Pregnant and lactating women.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Purdue University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stephen R Lindemann, PhD
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen Lindemann, PhD
Role: PRINCIPAL_INVESTIGATOR
Purdue University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Purdue University
West Lafayette, Indiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-2024-154
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.